A Phase I Open Label, Dose Escalation Study to Characterize the Safety, Tolerability, and Efficacy of VUM02 Injection in Subjects With Idiopathic Pulmonary Fibrosis
Latest Information Update: 23 Feb 2024
At a glance
- Drugs VUM 02 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms DEVIF-I
- Sponsors VCANBIO Cell and Gene Engineering
- 18 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Feb 2024.
- 18 Feb 2024 Status changed from not yet recruiting to recruiting.
- 06 Feb 2024 New trial record